The Most Common Issues in Preparing SEND: Explained by PointCross
  1. Life Sciences
  2. Nonclinical

Enhance Your SEND Submissions!

Written by Posted on Less than 0 min read

Join PointCross on May 29th, 2024, at 12 PM EST / 9 AM PST for a must-attend webinar: The Most Common Issues in Preparing SEND. Ideal for professionals in data submission and regulatory compliance, this webinar offers valuable insights from our seasoned experts.

Why Attend?

  • Identify Common Errors: Learn about frequent SEND errors and how to correct them.
  • Submission & Analysis Feedback: Receive expert feedback on submission processes and data analysis.
  • Quality Control: Discover QC methods to improve your data submission.

Why PointCross? With over 10 years of experience and more than 7,500 SEND datasets standardized, we offer top-notch services at the lowest cost. Don’t forget to check our free SEND Autoquote Generator: https://info.pointcrosslifesciences.com/send-quote-generation

🗓️ Register Now: Webinar: Common Issues in Preparing SEND (pointcrosslifesciences.com)

Member since
Contributor

More from Admin

  1. Clinical

First Affected person Dosed in Section 2a Medical Trial of a First-in-Class Regenerative Cell Remedy for Sufferers with Finish-Stage Liver Illness

PITTSBURGH, April 2, 2024. LyGenesis, a clinical-stage biotechnology firm growing cell therapies for big unmet medical wants, introduced right this moment that the primary affected person has been dosed of their Section 2a scientific trial evaluating their first-in-class allogenic regenerative cell remedy transplanted into sufferers’ lymph nodes as a possible remedy for […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Clinical

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers

Preliminary data from Arm A1 of the Phase 2 EDGE-Gastric study showed promising ORR and six-month PFS results, irrespective of PD-L1 expression Domvanalimab is the only Fc-silent anti-TIGIT antibody in Phase 3 for upper GI adenocarcinomas and has the potential to be first to market for these cancers FOSTER CITY, Calif., & […]
Written by
  1. Clinical

Innovent and SanegeneBio Announce First Participant Dosed in a Phase 1 Clinical Trial of IBI3016

SAN FRANSCISO and SUZHOU, China, Aug. 1, 2024. Innovent Biologics, Inc. (“Innovent”), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, and Sanegene Bio USA Inc. (SanegeneBio) today announced the first participant has been successfully dosed in a […]
Written by
  1. Clinical

Understanding the Role of Clinical Studies in Drug Development

Understanding the Role of Clinical Studies in Drug Development Clinical studies, also known as clinical trials, play a crucial role in the development of new drugs and medical interventions. They are an essential step in determining the safety and efficacy of a potential treatment before it can be approved and made available to the general […]
Written by
  1. Clinical

Geisinger enrolls first affected person in amyloid cardiomyopathy trial

DANVILLE, Pa., Could 10, 2024. Heart specialist Brendan Carry, MD, and a workforce of Geisinger physicians have enrolled the primary affected person within the U.S. right into a cardiac amyloidosis trial. The workforce can also be the primary to within the U.S. to display screen for the trial. “If a affected person qualifies for the […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

Cutting a few calories won’t hurt your workout

A new UC Riverside study demonstrates that calorie restriction doesn’t deter mice from exercising, challenging the belief that dieting drains workout energy. The study, published in the journal Physiology & Behavior, shows that cutting calories by 20% did not significantly reduce the distance that mice voluntarily chose to run each day. The researchers set out […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

Giant prehistoric flying reptile took off using similar method to bats, study finds

The pterosaur likely used all four limbs to propel itself in the air, as seen in bats today, researchers have found. The findings, published today in PeerJ, provide new insights into how pterosaurs managed to take flight despite reaching sizes far larger than modern animals. The research sheds new light on the flight initiating jumping […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

A new mechanism for shaping animal tissues

A key question that remains in biology and biophysics is how three-dimensional tissue shapes emerge during animal development. Research teams from the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG) in Dresden, Germany, the Excellence Cluster Physics of Life (PoL) at the TU Dresden, and the Center for Systems Biology Dresden (CSBD) have […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

Aligned peptide ‘noodles’ might allow lab-grown organic tissues

A staff of chemists and bioengineers at Rice College and the College of Houston have achieved a major milestone of their work to create a biomaterial that can be utilized to develop organic tissues outdoors the human physique. The event of a novel fabrication course of to create aligned nanofiber hydrogels might provide new potentialities […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

Largest protein yet discovered builds algal toxins

While seeking to unravel how marine algae create their chemically complex toxins, scientists at UC San Diego’s Scripps Institution of Oceanography have discovered the largest protein yet identified in biology. Uncovering the biological machinery the algae evolved to make its intricate toxin also revealed previously unknown strategies for assembling chemicals, which could unlock the development […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

Iconic savanna mammals face genetic issues because of fences and roads

Whether or not by the use of Attenborough, Disney or Nationwide Geographic, the enduring scene is acquainted to many. The bottom trembles and clouds of mud swirl as monumental hordes of enormous animals thunder throughout the African savanna, cross rivers en masse and are picked off by lions, hyena and crocodiles. The annual migration of […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

The rhythm led by plants is crucial for symbiosis with nutrient-providing bacteria

Legumes thrive in low-nitrogen environments by partnering with rhizobia, soil bacteria that convert atmospheric nitrogen into ammonium, a usable form for the plants. These beneficial bacteria are housed in root nodules formed on legume roots. However, the uncontrolled formation of numerous root nodules can impede root function. To prevent this, legumes need to regulate the […]
Written by
  1. Nonclinical

Shifting Perspectives: Embracing Nonclinical Roles in the Medical Field

Title: Shifting Perspectives: Embracing Nonclinical Roles in the Medical Field Introduction: In the ever-evolving landscape of the medical field, there has been a notable shift in perspectives and an increasing recognition of the value of nonclinical roles. While traditionally, the medical field primarily revolved around doctors and nurses, there is now a growing appreciation for […]
Written by
  1. Biology

Consensus paper: Carcinogenicity of gene therapies

Researchers from the University of Pennsylvania, Perelman School of Medicine, Gene Therapy Program, and Moderna, have shown that repeated administration of lipid nanoparticle-encapsulated mRNA therapy significantly extended survival and reduced serum leucine levels in a mouse model of maple syrup urine disease (MSUD). Click here to read the article now. The researchers, led by James Wilson, MD, […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Pharmaceuticals and Drug Development

FDA Approves Omvoh (mirikizumab-mrkz), a First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis

FDA Approves Omvoh (mirikizumab-mrkz), a First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis INDIANAPOLIS, Oct. 26, 2023 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh™ (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), the first and only interleukin-23p19 (IL-23p19) antagonist […]
Written by
FDA Approves First CAR T-Cell Therapy for Adults With Leukemia or Lymphoma
  1. Pharmaceuticals and Drug Development

FDA Approves First CAR T-Cell Remedy for Adults With Leukemia or Lymphoma

Medically reviewed by Medication.com. By Lori Solomon HealthDay Reporter MONDAY, March 18, 2024 — The U.S. Meals and Drug Administration has accredited Breyanzi (lisocabtagene maraleucel [liso-cel]) as the primary CD19-directed chimeric antigen receptor (CAR) T-cell remedy for grownup sufferers with relapsed or refractory power lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The expanded approval […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Pharmaceuticals and Drug Development

FDA Approves Arcutis’ Zoryve (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

WESTLAKE VILLAGE, Calif., July 09, 2024 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Zoryve (roflumilast) cream, 0.15%, for the treatment of mild to moderate atopic […]
Written by
Next
No Comments
Leave a comment Cancel
Comments to: Enhance Your SEND Submissions!

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.